8/F, 35 QRC Building, No.35 Queens Road, Central, Hong Kong

Doctor Introduction

Dr.Azzoli Doctor

Medical School: Johns Hopkins University School of Medicine; Residency: Johns Hopkins Hospital; Fellowship: Memorial Sloan-Kettering Cancer Center;

David White Doctor

Professor of clinical medicine at Harvard Medical School; Chief physician of the Division of Sleep Medicine in the Division of Laboratory Medicine at Harvard Brigham and Women's Hospital.

Jatin P. Shah Doctor

The Elliott W. Strong Chair in Head and Neck Oncology at Memorial Sloan-Kettering Cancer Center in New York City.




Phase 3 trial of Dupixent (dupi

Author: Magicure Date: 2023-03-20

On March 18 / hkmagicure , Regeneron and Sanofi presented positive results from the clinical trial assessing Dupixent (dupilumab) in adults and adolescents with uncontrolled moderate-to-severe atopic hand and foot dermati...

  • 11:2 wins! FDA ODAC Supports Ph

    Author: Magicure Date: 2023-03-10

    On March 10, Roche announced that the U.S. FDA Oncologic Drugs Advisory Committee (ODAC) voted 11 to 2 in favour of Polivy (polatuzumab vedotin-piiq) i...

  • The marketing application of Du

    Author: Magicure Date: 2023-03-08

    On March 7, Regeneron and Sanofi announced that the U.S. FDA has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent...

  • Phase 2 Clinical Trial Data of

    Author: Magicure Date: 2023-03-07

    On March 6, Positive topline results from an analysis of the ongoing DESTINY-PanTumor02 phase 2 trial showed treatment with Daiichi Sankyo and AstraZen...

  • CDK4/6 Inhibitor Verzenio Recei

    Author: Magicure Date: 2023-03-06

    On March 3, Lilly announced that the U.S. FDA approved an expanded indication for Verzenio (abemaciclib), in combination with endocrine therapy (ET), f...

  • Trodelvy (sacituzumab govitecan

    Author: Magicure Date: 2023-02-21

    On February 17, Gilead announced new and updated positive results from three cohorts of the Phase 2 TROPHY-U-01 study of Trodelvy (sacituzumab goviteca...

  • Trodelvy Approved by FDA for Me

    Author: Magicure Date: 2023-02-09

    Trodelvy (Sacituzumab Govitecan-hziy) is approved drug for the treatment of metastatic triple-negative breast cancer (mTNBC). It is a type of immunothe...

  • FDA approved Trodelvy for HR+/H

    Author: Magicure Date: 2023-02-06

    The Food and Drug Administration (FDA) approved Trodelvy (sacituzumab govitecan-hziy) for the treatment of patients with unresectable (not eligible to ...

  • “First in class” Targeted d

    Author: Magicure Date: 2023-02-03

    On February 2, AstraZeneca and Amgen announced the U.S. FDA has approved Tezspire (tezepelumab) for self-administration in a pre-filled, single-use pen...

About Magicure

Hong Kong Magicure Medical Center has long been focusing on the import and export of new drugs, special drugs and rare disease drugs in the field of oncology. At the same time, the medical center cooperates with a number of medical institutions in China and Hong Kong, and is committed to providing customers with efficient, convenient and safe medical services.

As an enterprise dedicated to providing safe, reliable and reassuring drugs for chronic diseases to hospitals, pharmacies and patients, Hong Kong Magicure Medical Co., Ltd. has always adhered to the business and sales tenet of honest management and attentive service and "focusing on oncology drugs and continuous improvement" The concept of "patient health", and strive to meet the medication needs of different hospitals, pharmacies and patients.